CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy

Christopher F. Spurney, Tesi Rocha Carolina, Erik Henricson, Julaine Florence, Jill Mayhew, Ksenija Gorni, Livia Pasquali, Alan Pestronk, Gerard R. Martin, Fengming Hu, Lei Nie, Anne M. Connolly, Diana M. Escolar

Research output: Contribution to journalArticle

Abstract

Introduction: Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle. Methods: We performed an open-label, 'add-on' pilot study of CoQ10 in thirteen 5-10-year-old DMD patients on steroids. The primary outcome measure was the total quantitative muscle testing (QMT) score. Results: Twelve of 16 children (mean age 8.03 ± 1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 μg/ml) were shown to be subjectand administration-dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in an 8.5% increase in muscle strength (P = 0.03). Conclusions: Addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD

Original languageEnglish (US)
Pages (from-to)174-178
Number of pages5
JournalMuscle and Nerve
Volume44
Issue number2
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

coenzyme Q10
Duchenne Muscular Dystrophy
Steroids
Muscle Strength
Muscles
Dystrophin
Standard of Care
Prednisone
Disease Progression
Adrenal Cortex Hormones
Therapeutics
Antioxidants

Keywords

  • Clinical trial
  • CoQ10
  • Duchenne muscular dystrophy
  • Muscle strength testing
  • Steroids

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Spurney, C. F., Carolina, T. R., Henricson, E., Florence, J., Mayhew, J., Gorni, K., ... Escolar, D. M. (2011). CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy. Muscle and Nerve, 44(2), 174-178. https://doi.org/10.1002/mus.22047

CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy. / Spurney, Christopher F.; Carolina, Tesi Rocha; Henricson, Erik; Florence, Julaine; Mayhew, Jill; Gorni, Ksenija; Pasquali, Livia; Pestronk, Alan; Martin, Gerard R.; Hu, Fengming; Nie, Lei; Connolly, Anne M.; Escolar, Diana M.

In: Muscle and Nerve, Vol. 44, No. 2, 08.2011, p. 174-178.

Research output: Contribution to journalArticle

Spurney, CF, Carolina, TR, Henricson, E, Florence, J, Mayhew, J, Gorni, K, Pasquali, L, Pestronk, A, Martin, GR, Hu, F, Nie, L, Connolly, AM & Escolar, DM 2011, 'CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy', Muscle and Nerve, vol. 44, no. 2, pp. 174-178. https://doi.org/10.1002/mus.22047
Spurney CF, Carolina TR, Henricson E, Florence J, Mayhew J, Gorni K et al. CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy. Muscle and Nerve. 2011 Aug;44(2):174-178. https://doi.org/10.1002/mus.22047
Spurney, Christopher F. ; Carolina, Tesi Rocha ; Henricson, Erik ; Florence, Julaine ; Mayhew, Jill ; Gorni, Ksenija ; Pasquali, Livia ; Pestronk, Alan ; Martin, Gerard R. ; Hu, Fengming ; Nie, Lei ; Connolly, Anne M. ; Escolar, Diana M. / CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy. In: Muscle and Nerve. 2011 ; Vol. 44, No. 2. pp. 174-178.
@article{cb45a72efb024560927582edaa211530,
title = "CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy",
abstract = "Introduction: Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle. Methods: We performed an open-label, 'add-on' pilot study of CoQ10 in thirteen 5-10-year-old DMD patients on steroids. The primary outcome measure was the total quantitative muscle testing (QMT) score. Results: Twelve of 16 children (mean age 8.03 ± 1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 μg/ml) were shown to be subjectand administration-dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in an 8.5{\%} increase in muscle strength (P = 0.03). Conclusions: Addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD",
keywords = "Clinical trial, CoQ10, Duchenne muscular dystrophy, Muscle strength testing, Steroids",
author = "Spurney, {Christopher F.} and Carolina, {Tesi Rocha} and Erik Henricson and Julaine Florence and Jill Mayhew and Ksenija Gorni and Livia Pasquali and Alan Pestronk and Martin, {Gerard R.} and Fengming Hu and Lei Nie and Connolly, {Anne M.} and Escolar, {Diana M.}",
year = "2011",
month = "8",
doi = "10.1002/mus.22047",
language = "English (US)",
volume = "44",
pages = "174--178",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy

AU - Spurney, Christopher F.

AU - Carolina, Tesi Rocha

AU - Henricson, Erik

AU - Florence, Julaine

AU - Mayhew, Jill

AU - Gorni, Ksenija

AU - Pasquali, Livia

AU - Pestronk, Alan

AU - Martin, Gerard R.

AU - Hu, Fengming

AU - Nie, Lei

AU - Connolly, Anne M.

AU - Escolar, Diana M.

PY - 2011/8

Y1 - 2011/8

N2 - Introduction: Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle. Methods: We performed an open-label, 'add-on' pilot study of CoQ10 in thirteen 5-10-year-old DMD patients on steroids. The primary outcome measure was the total quantitative muscle testing (QMT) score. Results: Twelve of 16 children (mean age 8.03 ± 1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 μg/ml) were shown to be subjectand administration-dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in an 8.5% increase in muscle strength (P = 0.03). Conclusions: Addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD

AB - Introduction: Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle. Methods: We performed an open-label, 'add-on' pilot study of CoQ10 in thirteen 5-10-year-old DMD patients on steroids. The primary outcome measure was the total quantitative muscle testing (QMT) score. Results: Twelve of 16 children (mean age 8.03 ± 1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 μg/ml) were shown to be subjectand administration-dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in an 8.5% increase in muscle strength (P = 0.03). Conclusions: Addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD

KW - Clinical trial

KW - CoQ10

KW - Duchenne muscular dystrophy

KW - Muscle strength testing

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=79960497177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960497177&partnerID=8YFLogxK

U2 - 10.1002/mus.22047

DO - 10.1002/mus.22047

M3 - Article

C2 - 21698649

AN - SCOPUS:79960497177

VL - 44

SP - 174

EP - 178

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 2

ER -